Dogwood Therapeutics receives Nasdaq delisting notice for low stockholders' equity

Dogwood Therapeutics, Inc.

Stockholders' equity fell below $2.5M minimum per Q3 2024 10-Q; delisting risk under Nasdaq Rule 5550(b)(1).
Company has until December 30, 2024 to submit a compliance plan; Nasdaq may grant up to 180-day extension.
Acquisition of Pharmagesic closed Oct 7, 2024, after the Q3 report, not reflected in equity calculation.
No immediate effect on listing; common stock (DWTX) continues trading on Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.